Bio-Rad Laboratories Company Profile (NYSE:BIO)

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:BIO
  • CUSIP: 09057220
  • Web: www.bio-rad.com
Capitalization:
  • Market Cap: $6.48 billion
  • Outstanding Shares: 29,605,000
Average Prices:
  • 50 Day Moving Avg: $214.33
  • 200 Day Moving Avg: $193.77
  • 52 Week Range: $135.94 - $224.24
P/E:
  • Trailing P/E Ratio: 232.43
  • Foreward P/E Ratio: 48.33
  • P/E Growth: 5.46
Sales & Book Value:
  • Annual Revenue: $2.1 billion
  • Price / Sales: 3.09
  • Book Value: $91.45 per share
  • Price / Book: 2.39
Profitability:
  • EBIDTA: $271.79 million
  • Net Margins: 4.75%
  • Return on Equity: 3.79%
  • Return on Assets: 2.56%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 4.18%
  • Quick Ratio: 2.92%
Misc:
  • Average Volume: 221,237 shs.
  • Beta: 0.89
  • Short Ratio: 4.54
 

Frequently Asked Questions for Bio-Rad Laboratories (NYSE:BIO)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Thursday, May, 4th. The company reported $0.41 EPS for the quarter, beating the Zacks' consensus estimate of $0.27 by $0.14. The firm had revenue of $500.05 million for the quarter, compared to the consensus estimate of $477.76 million. Bio-Rad Laboratories had a net margin of 4.75% and a return on equity of 3.79%. The firm's revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.42 EPS. View Bio-Rad Laboratories' Earnings History.

When will Bio-Rad Laboratories make its next earnings announcement?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Bio-Rad Laboratories.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

3 equities research analysts have issued 1-year target prices for Bio-Rad Laboratories' stock. Their forecasts range from $180.00 to $250.00. On average, they expect Bio-Rad Laboratories' share price to reach $208.33 in the next twelve months. View Analyst Ratings for Bio-Rad Laboratories.

What are analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (5/1/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.86%), Vanguard Group Inc. (5.66%), Acadian Asset Management LLC (3.03%), Ariel Investments LLC (2.28%), TimesSquare Capital Management LLC (2.07%) and State Street Corp (1.81%). Company insiders that own Bio-Rad Laboratories stock include James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Ariel Investments LLC, Granahan Investment Management Inc. MA, Russell Investments Group Ltd., Wells Fargo & Company MN, Tudor Investment Corp ET AL, Acadian Asset Management LLC and UBS Asset Management Americas Inc.. Company insiders that have sold Bio-Rad Laboratories stock in the last year include James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., BlueCrest Capital Management Ltd, TimesSquare Capital Management LLC, Point72 Asset Management L.P., Vanguard Group Inc., FMR LLC, Neuberger Berman Group LLC and Spark Investment Management LLC. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bio-Rad Laboratories stock cost?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $218.95.

Analyst Ratings

Consensus Ratings for Bio-Rad Laboratories (NYSE:BIO) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $208.33 (4.85% downside)

Analysts' Ratings History for Bio-Rad Laboratories (NYSE:BIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Jefferies Group LLCReiterated RatingBuy$250.00LowView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$195.00N/AView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
11/4/2015Leerink SwannBoost Price Target$143.00 -> $149.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Bio-Rad Laboratories (NYSE:BIO)
Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Earnings History by Quarter for Bio-Rad Laboratories (NYSE:BIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Rad Laboratories (NYSE:BIO)
2017 EPS Consensus Estimate: $3.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.41$0.41$0.41
Q2 20171$0.81$0.81$0.81
Q3 20171$0.50$0.50$0.50
Q4 20171$1.40$1.40$1.40
Q1 20181$1.05$1.05$1.05
Q2 20181$1.33$1.33$1.33
Q3 20181$1.06$1.06$1.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Rad Laboratories (NYSE:BIO)
Insider Ownership Percentage: 28.38%
Institutional Ownership Percentage: 64.29%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.00View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Rad Laboratories (NYSE:BIO)
Latest Headlines for Bio-Rad Laboratories (NYSE:BIO)
Source:
DateHeadline
prnewswire.com logoProtein Assays Market Worth 2.41 Billion USD by 2022
www.prnewswire.com - May 25 at 1:54 AM
finance.yahoo.com logoBio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient Results with the IH-1000 System
finance.yahoo.com - May 24 at 8:51 PM
finance.yahoo.com logoInside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
finance.yahoo.com - May 22 at 3:52 PM
finance.yahoo.com logoInside Bio-Rad Laboratories’ Profit Margin Expectations in 2017
finance.yahoo.com - May 22 at 3:52 PM
finance.yahoo.com logoBio-Rad Laboratories on the Street: Analysts’ Recommendations in May
finance.yahoo.com - May 22 at 11:29 AM
americanbankingnews.com logo Bio-Rad Laboratories, Inc. (BIO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 16 at 6:42 PM
marketwatch.com logoIn Vitro Diagnostics (IVD) Market in BRIC Growing at a CAGR of 8.2% During 2017 to 2022 - ReportsnReports
www.marketwatch.com - May 15 at 4:04 PM
finance.yahoo.com logoSTERIS (STE) Grapples with Headwinds: Should You Dump?
finance.yahoo.com - May 12 at 4:30 PM
finance.yahoo.com logoMedtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
finance.yahoo.com - May 12 at 4:30 PM
americanbankingnews.com logoJefferies Group Research Analysts Decrease Earnings Estimates for Bio-Rad Laboratories, Inc. (BIO)
www.americanbankingnews.com - May 8 at 9:06 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Releases Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - May 5 at 8:08 PM
finance.yahoo.com logoEdited Transcript of BIO earnings conference call or presentation 4-May-17 9:00pm GMT
finance.yahoo.com - May 5 at 3:56 PM
seekingalpha.com logoBio-Rad Laboratories (BIO) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 2:04 AM
finance.yahoo.com logoBio-Rad Reports First-Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 9:04 PM
finance.yahoo.com logoBio-Rad posts 1Q profit
finance.yahoo.com - May 4 at 9:04 PM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Affect Bio-Rad Laboratories (BIO) Share Price
www.americanbankingnews.com - May 4 at 4:32 PM
bizjournals.com logoThe transplantation diagnostics market is estimated to rise at a high double digit CAGR to reach $2,059.2 million by 2022.
www.bizjournals.com - May 3 at 1:13 PM
bizjournals.com logoThe Biosensor market is expected to grow to 27.06 Billion USD by 2022
www.bizjournals.com - May 2 at 3:57 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 11:24 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 1 at 8:16 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Impact Bio-Rad Laboratories (BIO) Share Price
www.americanbankingnews.com - May 1 at 2:36 PM
americanbankingnews.com logoBio-Rad Laboratories (BIO) Earns Daily News Sentiment Score of 0.26
www.americanbankingnews.com - April 28 at 11:08 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 27 at 2:28 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $0.27 Per Share
www.americanbankingnews.com - April 27 at 8:04 AM
bizjournals.com logoGlobal Immunoassay Systems - Laboratory Equipment and Supplies
www.bizjournals.com - April 26 at 12:40 PM
americanbankingnews.com logoBio-Rad Laboratories (BIO) Receives Media Impact Score of -0.02
www.americanbankingnews.com - April 21 at 12:28 PM
finance.yahoo.com logoETFs with exposure to Bio-Rad Laboratories, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 4:02 PM
americanbankingnews.com logo Bio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 20 at 3:20 PM
americanbankingnews.com logoFavorable Media Coverage Likely to Impact Bio-Rad Laboratories (BIO) Share Price
www.americanbankingnews.com - April 18 at 1:07 PM
americanbankingnews.com logoBio-Rad Laboratories (BIO) Receives Daily Coverage Optimism Rating of 0.39
www.americanbankingnews.com - April 15 at 12:33 PM
americanbankingnews.com logoBio-Rad Laboratories' (BIO) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - April 11 at 12:00 PM
finance.yahoo.com logoBio-Rad to Report First-Quarter 2017 Financial Results Thursday, May 4, 2017 - Yahoo Finance
finance.yahoo.com - April 10 at 3:52 PM
finance.yahoo.com logoBio-Rad to Report First-Quarter 2017 Financial Results Thursday, May 4, 2017
finance.yahoo.com - April 10 at 3:52 PM
americanbankingnews.com logo Analysts Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Announce Quarterly Sales of $474.74 Million
www.americanbankingnews.com - April 7 at 8:45 PM
bizjournals.com logoHealthTell, Inc. appoints Isaac J. Bright, MD as Chief Business Officer
www.bizjournals.com - April 7 at 8:29 AM
reuters.com logoFitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable
www.reuters.com - April 7 at 8:29 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $0.27 Per Share
www.americanbankingnews.com - April 5 at 10:22 PM
americanbankingnews.com logo Brokerages Set $230.00 Target Price for Bio-Rad Laboratories, Inc. (BIO)
www.americanbankingnews.com - April 5 at 10:22 AM
prnewswire.com logoMicrofluidic Chips Market by Polymers, Ceramics and Semi - Conductors Type and Applications Analysis by 2022 Available at ReportsnReports.com
www.prnewswire.com - March 31 at 9:05 PM
prnewswire.com logoLab on Chips Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
www.prnewswire.com - March 21 at 9:17 PM
americanbankingnews.com logoZacks: Bio-Rad Laboratories, Inc. (BIO) Given Consensus Rating of "" by Analysts
www.americanbankingnews.com - March 20 at 12:22 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. Expected to Post FY2020 Earnings of $10.00 Per Share (BIO)
www.americanbankingnews.com - March 15 at 1:30 PM
finance.yahoo.com logoIn Vitro Diagnostics/IVD Market by Product, Technology, Application - Forecast to 2021
finance.yahoo.com - March 14 at 8:41 AM
finance.yahoo.com logoBio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day
finance.yahoo.com - March 13 at 11:12 AM
finance.yahoo.com logo8:32 am Bio-Rad Labs provides long term financial guidance, to propose three new independent directors; reiterates 2017 financial outlook
finance.yahoo.com - March 13 at 11:12 AM
biz.yahoo.com logoBIO RAD LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - March 13 at 11:12 AM
americanbankingnews.com logoInsider Selling: Bio-Rad Laboratories, Inc. (BIO) EVP Sells 300 Shares of Stock
www.americanbankingnews.com - March 8 at 11:54 PM
finance.yahoo.com logoMultiplex Assays Market by Product, Type, Technology, Application, End User - Global Forecast to 2021
finance.yahoo.com - March 8 at 9:38 PM
finance.yahoo.com logoBIO RAD LABORATORIES INC Financials
finance.yahoo.com - March 4 at 4:26 PM
biz.yahoo.com logoBIO RAD LABORATORIES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 1 at 8:39 AM

Social

Chart

Bio-Rad Laboratories (BIO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff